Get the Stockscreener App
241.47
0.15%
-0.075
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $241.47, with a volume of 66,320.
It is down -0.15% in the last 24 hours and up +0.48% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$241.55
Open:
$242.52
24h Volume:
66,320
Relative Volume:
0.07
Market Cap:
$35.10B
Revenue:
$4.81B
Net Income/Loss:
$1.11B
P/E Ratio:
39.20
EPS:
6.16
Net Cash Flow:
$1.35B
1W Performance:
+4.22%
1M Performance:
+0.48%
6M Performance:
+10.50%
1Y Performance:
+58.14%
1-Day Range:
$240.69
$242.75
1-Week Range:
$231.17
$242.75
52-Week Range:
$151.95
$260.49
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RMD | 241.30 | 35.10B | 4.81B | 1.11B | 1.35B | 6.16 |
| ISRG | 546.29 | 191.57B | 7.87B | 2.24B | 586.00M | 4.25 |
| BDX | 222.83 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
| ALC | 85.82 | 42.29B | 9.76B | 1.16B | 665.00M | 0.72 |
| WST | 315.15 | 22.14B | 2.88B | 499.60M | 321.60M | 7.41 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed Inc. Officer Plans Major Stock Sale - MSN
Caprock Group LLC Acquires 2,806 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Acquired by Natixis Advisors LLC - MarketBeat
ResMed Inc. (NYSE:RMD) Shares Acquired by Empowered Funds LLC - MarketBeat
ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year - MSN
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
3 Reasons Why Growth Investors Shouldn't Overlook ResMed (RMD) - Yahoo Finance
3,041 Shares in ResMed Inc. (NYSE:RMD) Acquired by Retireful LLC - MarketBeat
Resmed Inc Announces Upcoming Stock Sale - MSN
Meeder Asset Management Inc. Buys 3,174 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
3 ASX shares Australians can buy and hold for the next decade - MSN
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Second Half Financial Partners LLC Takes Position in ResMed Inc. (NYSE:RMD) - MarketBeat
LGT Capital Partners LTD. Decreases Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
LMR Partners LLP Sells 18,741 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
Top broker says buy ResMed and this ASX 200 share - MSN
Publication relating to transparency notifications, Business Wires News - AsiaOne
Nyxoah’s Voting Rights Shift with ResMed Stake - TipRanks
Publication relating to transparency notifications - The Manila Times
ResMed's Stake in Nyxoah Drops Below 5% Threshold in Latest Holdings Update | NYXH Stock News - StockTitan
ResMed Inc. (NYSE:RMD) Shares Acquired by Mawer Investment Management Ltd. - MarketBeat
ResMed's (NYSE:RMD) earnings growth rate lags the 11% CAGR delivered to shareholders - Yahoo Finance
Victory Capital Management Inc. Has $28.49 Million Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed (ASX:RMD) 3-Year EBITDA Growth Rate : 11.10% (As of Sep. 2024) - GuruFocus.com
KBC Group NV Increases Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. stock rises Friday, outperforms market - MarketWatch
What is Zacks Research's Forecast for ResMed Q1 Earnings? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Increases Position in ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Insider Sale: Director Witte De Sells Shares of ResMed Inc (RMD) - GuruFocus.com
ResMed director Jan De Witte sells shares worth $198,052 - Investing.com
ResMed Inc Insider Sells Shares, Retains Ownership - MSN
What is Zacks Research's Forecast for ResMed Q2 Earnings? - MarketBeat
Insiders At ResMed Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance Australia
Baillie Gifford & Co. Lowers Stake in ResMed Inc. (NYSE:RMD) - MarketBeat
Versor Investments LP Sells 2,400 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat
ResMed CFO Brett Sandercock sells $249,000 in stock - Investing.com India
ResMed Inc. stock falls Wednesday, underperforms market - MarketWatch
OVERSEA CHINESE BANKING Corp Ltd Has $4.75 Million Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Entropy Technologies LP Invests $1.87 Million in ResMed Inc. (NYSE:RMD) - MarketBeat
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why - Simply Wall St
ResMed’s Peter Farrell Adjusts Stock Holdings - TipRanks
ResMed Inc Director Adjusts Stock Holdings - TipRanks
ResMed’s Executive Stock Transactions Highlight Compensation Practices - TipRanks
ResMed Inc. CEO Executes Strategic Stock Transactions - TipRanks
ResMed Inc’s Executive Share Transactions Revealed - TipRanks
ResMed CFO Sandercock Sells 1,000 Shares - TipRanks
ResMed Updates Dividend Details for ASX CDI Holders - TipRanks
Zacks.com featured highlights include Greenbrier, Walmart, Leidos, InterDigital and ResMed - Yahoo Finance
ResMed Inc. (NYSE:RMD) Shares Bought by Principal Financial Group Inc. - MarketBeat
Los Angeles Capital Management LLC Lowers Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):